Work

Euglycemic diabetic ketoacidosis with canagliflozin: Not-so-sweet but avoidable complication of sodium-glucose cotransporter-2 inhibitor use.

Year: 2016

Type: article

Abstract: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been approved in Canada for use in the management of type 2 diabetes (T2DM) since May 2014. Three agents from this class are licensed in Canada (canagliflozin, dapagliflozin, and empagliflozin). These agents are likely to be used commonly in

Source: Europe PMC (PubMed Central)

Authors: Maureen Clement, Peter Senior

Institutions: Interior Health, University of British Columbia, University of Alberta

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2520711045

FWCI: 2.301

Cites: 7

Cited by: 14

Related to: 10